Supplement deep dive

Uridine Monophosphate: The Overlooked Membrane Cofactor

Choline gets the attention. Its partner in the Kennedy pathway — uridine — barely gets a mention. But without it, choline can't build the membranes it's famous for supporting.

📅 Published September 7, 2026 ⏱ 7 min read 📚 6 peer-reviewed citations
Affiliate disclosure: Some links below are Amazon Associates or telehealth partner links. If you buy through them we may earn a commission at no cost to you. We only recommend products backed by peer-reviewed research — read our editorial standards.
The bottom line

Uridine monophosphate is a pyrimidine nucleotide that partners with choline and DHA in the Kennedy pathway — the biochemical route neurons use to build phosphatidylcholine and phosphatidylethanolamine, the two dominant neuronal membrane phospholipids. Richard Wurtman's MIT lab established the uridine + choline + DHA triad, which became the basis for Souvenaid (a medical food for early Alzheimer's). Standard uridine supplement dose is 150-500 mg daily, ideally stacked with choline and DHA.

What uridine actually is

Uridine is a pyrimidine nucleoside — one of the four RNA building blocks, alongside adenosine, guanosine, and cytidine. In supplements, it's typically sold as uridine-5'-monophosphate (UMP), which is uridine attached to a phosphate group. UMP disodium is the most stable and bioavailable form.

Uridine is present in trace amounts in foods — sugar cane, tomato products, brewer's yeast, mushrooms, and organ meats are the more concentrated sources. Human breast milk contains meaningful amounts (part of what makes it uniquely suited to infant brain development). Standard adult diets provide milligrams to tens of milligrams daily — substantially less than supplement doses (150-500 mg).

Uridine crosses the blood-brain barrier via specific nucleoside transporters and is taken up efficiently by neurons.

Why brain neurons care about uridine

The critical biochemistry: neurons continuously turn over their membrane phospholipids. Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are the two dominant membrane phospholipids, and they're synthesized through the Kennedy pathway — a biochemical cycle requiring three main inputs:

All three are required. Rate-limiting availability of any one caps the pathway's output. In young healthy brains with adequate diet, endogenous supply of all three is typically sufficient. In aging brains, in stroke recovery, and potentially in early neurodegenerative disease, the supply of any of these can become rate-limiting for membrane synthesis and repair.

This is where uridine supplementation earns its place — not as a standalone brain miracle, but as the often-overlooked third leg of the phospholipid synthesis tripod.

The Wurtman research and Souvenaid

Richard Wurtman's MIT laboratory established much of the biochemistry linking uridine, choline, and DHA to phosphatidylcholine synthesis and synapse formation. Cansev & Wurtman 2007 demonstrated that combining all three — uridine, choline, and DHA — in rat feeding studies produced significantly more synaptic membrane protein synthesis than any individual component.[1]

This research became the basis for Souvenaid — a medical food developed by Nutricia (Danone) specifically for early Alzheimer's disease. Souvenaid combines uridine monophosphate + DHA + EPA + choline + phospholipids + B vitamins + antioxidants (the "Fortasyn Connect" formulation).

The LipiDiDiet trial — Soininen 2017 — tested Souvenaid in 311 patients with prodromal Alzheimer's disease (before dementia onset) for 24 months. Cognitive decline on the CDR-SB (Clinical Dementia Rating Sum of Boxes) was significantly reduced in the treatment group vs placebo. Hippocampal atrophy was also reduced.[2]

Two-year follow-up (Soininen 2021) confirmed sustained benefits — the treatment group showed slower cognitive and functional decline.[3]

Souvenaid isn't a supplement — it's a medical food available in Europe (not approved as such in the US). But its constituent ingredients, including uridine, are all commercially available as supplements. Replicating the Souvenaid stack via individual supplements is a reasonable approach for people wanting the underlying nutritional intervention.

STRONG: Uridine + choline + DHA combination for membrane phospholipid synthesis (Wurtman + replications, mechanistic).MODERATE: Combined uridine+choline+DHA-based Souvenaid for prodromal Alzheimer's disease (Soininen LipiDiDiet trial).EMERGING: Uridine monotherapy for cognitive endpoints (limited direct trial evidence).

The mood evidence — an unexpected angle

Uridine has some emerging mood-support evidence separate from the membrane synthesis story. Jensen 2008 tested a proprietary uridine + omega-3 formulation in 20 adolescents with bipolar depression over 6 weeks. Response rates were significantly higher than expected from placebo alone.[4]

This isn't a large or definitive trial, and it's not FDA-approved for depression. But there's mechanistic plausibility — uridine influences dopamine and cAMP signaling in brain regions relevant to mood, and the phospholipid synthesis mechanism is relevant to neuronal membrane repair after depressive episodes.

For most consumer purposes, uridine's primary rationale remains the membrane-synthesis stack. The mood evidence is worth knowing as adjacent context but not a primary reason to purchase.

Dosing and stacking

Standard uridine dosing

Monotherapy: 150-500 mg UMP disodium daily. Some protocols split as 150-250 mg morning + 150-250 mg midday.

Stacked with choline and DHA (the Souvenaid pattern): 250-500 mg UMP + 250-500 mg citicoline (or Alpha-GPC) + 500-1,000 mg DHA daily. This is the mechanistically complete stack.

Take with food — uridine absorbs well with meals. No specific timing requirement.

Sublingual vs oral: Some uridine products are sold as sublingual tablets or troches. The rationale is bypassing first-pass liver metabolism. The clinical evidence for meaningfully improved bioavailability via sublingual delivery is limited. Standard oral UMP disodium at trial-verified doses is generally sufficient.

Cost: Uridine is moderately expensive per gram — a 300 mg daily protocol typically runs $20-35/month for quality UMP. Not the cheapest single-supplement addition, but reasonable given the mechanistic contribution to the Souvenaid stack.

Who benefits, who should skip

Uridine is a fit for:

Consider carefully or skip if:

The DIY Souvenaid approach

Since Souvenaid isn't available in the US, some people build the stack from individual components. A reasonable approximation:

This isn't a substitute for medical evaluation if someone has actual prodromal or diagnosed Alzheimer's. It's a nutritional pattern with reasonable mechanistic support and one supportive medical-food clinical trial. For older adults with subjective cognitive concerns and family history, it's a defensible protocol.

What to actually buy

BEST UMP DISODIUM

Nootropics Depot Uridine Monophosphate

300 mg UMP disodium capsules, third-party tested. One of the more transparent brands in the nucleotide supplement space.

Check Amazon price →
BUDGET UMP

Double Wood Uridine Monophosphate

300 mg UMP capsules at lower per-serving cost. Solid third-party testing for the price point.

Check Amazon price →
SUBLINGUAL UMP OPTION

Liftmode Uridine Monophosphate

UMP sublingual/powder format for users who prefer the sublingual approach. Bulk powder allows flexible dosing.

Check Amazon price →

Citations

  1. Cansev M, Wurtman RJ. Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience. 2007;148(2):421-431.
  2. Soininen H, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(12):965-975.
  3. Soininen H, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimers Dement. 2021;17(1):29-40.
  4. Kondo DG, et al. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2011;21(2):171-175.
  5. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr. 2009;29:59-87.
  6. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007;1182:50-59.
Editorial note: This article summarizes peer-reviewed research current as of publication. Nothing here is medical advice — talk to your doctor before starting or changing supplements, especially if you take prescriptions. Affiliate links help fund the research work.